What's in AOP Orphan Pharmaceuticals AG's pipeline?

AOP Orphan Pharmaceuticals AG has 13 drugs in our index: 2 marketed, 0 filed, 5 in Phase 3, 3 in Phase 2, 3 in Phase 1.

Which companies overlap with AOP Orphan Pharmaceuticals AG's portfolio?

Top competitors by shared drug class: Civi Biopharma, Inc., GlaxoSmithKline, Konkuk University Medical Center, Liquidia Technologies, Inc., Ludwig-Maximilians - University of Munich.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/aop-orphan-pharmaceuticals-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

AOP Orphan Pharmaceuticals AG — Portfolio Competitive Intelligence Brief

AOP Orphan Pharmaceuticals AG pipeline: 2 marketed, 0 filed, 5 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 5 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Standard of Care - Double Oral	Standard of Care - Double Oral	marketed	Antithrombotic combination therapy		Cardiovascular
Brevibloc	Brevibloc	marketed		Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor	Cardiovascular
Anagrelide retard	Anagrelide retard	phase 3	Phosphodiesterase 3 inhibitor	Phosphodiesterase 3 (PDE3)	Hematology/Oncology
Thromboreductin	Thromboreductin	phase 3			Cardiovascular
Pegylated-Proline-interferon alpha-2b	Pegylated-Proline-interferon alpha-2b	phase 3	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)	Virology/Hepatology
preservative-free parenteral treprostinil	preservative-free parenteral treprostinil	phase 3	Prostacyclin analog	Prostacyclin receptor (IP receptor)	Cardiovascular
Peg-P-IFN-alpha-2b (AOP2014)	Peg-P-IFN-alpha-2b (AOP2014)	phase 3	Pegylated interferon alpha	Interferon alpha receptor (IFNAR)	Virology / Immunology

Therapeutic area mix

Cardiovascular · 4
Hematology/Oncology · 1
Virology / Immunology · 1
Virology/Hepatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Civi Biopharma, Inc. · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Konkuk University Medical Center · 1 shared drug class
Liquidia Technologies, Inc. · 1 shared drug class
Ludwig-Maximilians - University of Munich · 1 shared drug class
Lung Biotechnology PBC · 1 shared drug class
The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class
The Second Affiliated Hospital of Chongqing Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AOP Orphan Pharmaceuticals AG:

Cite this brief

Drug Landscape (2026). AOP Orphan Pharmaceuticals AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aop-orphan-pharmaceuticals-ag. Accessed 2026-05-16.